Physician profile
Mark H Blecher
NPI 1356343248
$357,306.11
in general payments reported to CMS, 2019-2025
17 companies · $8,473 in 2025
The $8,473 reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134K · 2020: $69K · 2021: $57K · 2022: $37K · 2023: $34K · 2024: $17K · 2025: $8,473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $56K · Food and Beverage: $4,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $55,850.00 |
| Food and Beverage | $4,038.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $347,672.46 | 2019-2025 | Ifs Advanced Femtosec Laser, Compact Intuitiv, Catalys System |
| Bausch & Lomb Americas INC. | $6,389.26 | 2023-2025 | Ic-8 Apthera Iol, Miebo, Xipere |
| Abbvie INC. | $1,000.00 | 2022 | |
| Alcon Vision LLC | $906.17 | 2021-2025 | Clareon, Centurion |
| Rxsight INC | $287.27 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Biotissue Holdings INC. | $224.20 | 2019 | |
| Quidel Corporation | $171.70 | 2019 | |
| Allergan, INC. | $124.99 | 2019 | |
| Glaukos Corporation | $120.58 | 2020 | |
| Harrow Eye, LLC | $106.61 | 2025 | |
| Kala Pharmaceuticals, INC. | $91.30 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $75.68 | 2023 | Acuvue |
| Leica Microsystems INC. | $48.02 | 2024 | Surgical Microscopes |
| Eyepoint US, INC. | $46.96 | 2019 | |
| Ocular Therapeutix, INC. | $23.81 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $17.10 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$180,240.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Blecher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.